ZYME

Business Context and Reporting Period

Zymeworks Inc. is a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics for cancer and autoimmune diseases. This Form 10-Q covers the quarterly period ended March 31, 2025. The company operates as a single reportable segment focused on the discovery, development, and commercialization of biotherapeutics. Its lead asset, zanidatamab (Ziihera), received FDA accelerated approval in late 2024 for HER2-positive biliary tract cancer and is being commercialized by partner Jazz Pharmaceuticals.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased by 171% to $27.1 million, driven primarily by non-recurring milestone payments. The company recognized $14.0 million from GSK (clinical milestone) and $3.1 million from Daiichi Sankyo (first patient dosed milestone).
• Improved Operating Loss: Operating loss narrowed by $12.2 million to $25.6 million, largely due to the significant revenue recognition offsetting increased operating expenses.
• Expense Shifts: R&D expenses rose 12% to $35.7 million, primarily due to increased spending on the ZW251 program (IND-enabling studies) and other preclinical activities. This was partially offset by reduced costs for zanidatamab and zanidatamab zovodotin following strategic decisions to discontinue or transfer development.
• Cash Flow Improvement: Net cash used in operating activities decreased significantly to $3.4 million from $37.7 million in the prior year, attributed to favorable working capital movements, specifically a $31.2 million decrease in accounts receivable.
• Interest Income Decline: Interest income dropped to $3.4 million from $5.9 million due to lower average yields and reduced balances of cash and marketable securities.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management anticipates that existing cash, cash equivalents, and marketable securities ($321.6 million) will fund operations for at least the next 12 months. No specific financial guidance was provided for future periods.
• Pipeline Progress:
  • Zanidatamab: EMA CHMP adopted a positive opinion for conditional marketing authorization in the EU. A BLA is under review in China. Top-line results from the HERIZON-GEA-01 study are expected in H2 2025.
  • ZW171 & ZW191: Both are in ongoing global Phase 1 studies. ZW171 targets mesothelin-expressing cancers; ZW191 targets folate receptor alpha-expressing tumors.
  • ZW251: IND submission for Phase 1 studies is expected by mid-2025.
• Key Risks:
  • Regulatory Dependence: Success depends on partners (Jazz, BeiGene) achieving regulatory approvals and commercial milestones. Failure of confirmatory trials for zanidatamab could lead to market withdrawal.
  • Capital Requirements: The company expects to continue incurring losses and will require substantial additional funding to advance its pipeline. Future financing may result in dilution.
  • Third-Party Reliance: Reliance on third-party manufacturers and CROs introduces supply chain and execution risks.
  • Intellectual Property: Risks related to patent validity, enforcement, and potential infringement claims.

Investor Verification Checklist

• Verify the timing and certainty of the European Commission's final decision on zanidatamab following the positive CHMP opinion.
• Confirm the status of the confirmatory trial for zanidatamab in the U.S. required to maintain accelerated approval.
• Monitor the progress of the ZW251 IND submission expected in mid-2025 and the initiation of Phase 1 trials for ZW171 and ZW191.
• Assess the sustainability of the $321.6 million cash runway given the company's burn rate and potential need for future equity financing.
• Review the terms of the collaboration agreements with Jazz and BeiGene regarding milestone triggers and royalty rates.